|

Anti-PD-1 antibody drug named Serplulimab Clinical Trials

1 actively recruiting trial

Pipeline

Phase 3: 1

Top Sponsors

  • West China Hospital1

Indications

  • Anal Function Preservation1
  • Total Neoadjuvant Therapy1
  • Locally Advanced Rectal Cancer (LARC)1
  • Radiotherapy1
  • Immunotherapy1

Other1 trial

Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.